Literature DB >> 26820273

Balance between Hyperinflammation and Immunosuppression in Sepsis.

Hemang Yadav1, Rodrigo Cartin-Ceba1.   

Abstract

Sepsis is a major cause of morbidity and mortality among hospitalized patients and the leading cause of death among patients admitted to intensive care units. The immune response in sepsis is characterized by the activation of both proinflammatory and anti-inflammatory pathways. These pathways are concurrent, starting early in the course of sepsis. Given the high burden of morbidity and mortality associated with sepsis, there is an increasing interest in immunomodulatory therapies targeted at improving outcomes in sepsis. This review will summarize current understanding about the balance between hyperinflammation and immunosuppression in sepsis and discuss the role of potential therapies to modulate these responses. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26820273     DOI: 10.1055/s-0035-1570356

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  12 in total

Review 1.  Mitophagy Contributes to the Pathogenesis of Inflammatory Diseases.

Authors:  Yan Zhao; Shaohui Huang; Jie Liu; Ximing Wu; Shuai Zhou; Ke Dai; Yurong Kou
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

2.  Proteomic changes of CD4+/CD25+/forkhead box p3+ regulatory T cells in a 30-day rat model of sepsis survival.

Authors:  Yuxia Jiao; Siqi Tan; Junyu Xiong
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

3.  miR‑23a downregulation modulates the inflammatory response by targeting ATG12‑mediated autophagy.

Authors:  Xiang Si; Daiyin Cao; Juan Chen; Yao Nie; Zhiyi Jiang; Min-Ying Chen; Jian-Feng Wu; Xiang-Dong Guan
Journal:  Mol Med Rep       Date:  2018-05-29       Impact factor: 2.952

4.  Alleviation of exhaustion-induced immunosuppression and sepsis by immune checkpoint blockers sequentially administered with antibiotics-analysis of a new mathematical model.

Authors:  Avi Gillis; Michael Beil; Karin Halevi-Tobias; Peter Vernon van Heerden; Sigal Sviri; Zvia Agur
Journal:  Intensive Care Med Exp       Date:  2019-06-11

Review 5.  HSP-Target of Therapeutic Agents in Sepsis Treatment.

Authors:  Anderson Vulczak; Carlos Henrique Rocha Catalão; Luiz Alexandre Pedro de Freitas; Maria José Alves Rocha
Journal:  Int J Mol Sci       Date:  2019-08-30       Impact factor: 5.923

6.  Inhibition of PTP1B Promotes M2 Polarization via MicroRNA-26a/MKP1 Signaling Pathway in Murine Macrophages.

Authors:  Xiaolong Xu; Xuerui Wang; Yuhong Guo; Yunjing Bai; Shasha He; Ning Wang; Yan Lin; Marc Fisher; Qingquan Liu; Yongming Yao
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

7.  Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance.

Authors:  Emely Verweyen; Dirk Holzinger; Toni Weinhage; Claas Hinze; Helmut Wittkowski; Peter Pickkers; Sabrin Albeituni; Katherine Verbist; Kim E Nichols; Grant Schulert; Alexei Grom; Dirk Foell; Christoph Kessel
Journal:  Am J Respir Crit Care Med       Date:  2020-03-01       Impact factor: 21.405

Review 8.  Immune Modulation in Critically Ill Septic Patients.

Authors:  Salvatore Lucio Cutuli; Simone Carelli; Domenico Luca Grieco; Gennaro De Pascale
Journal:  Medicina (Kaunas)       Date:  2021-05-31       Impact factor: 2.430

9.  Interleukin-38 protects against sepsis by augmenting immunosuppressive activity of CD4+ CD25+ regulatory T cells.

Authors:  Yun Ge; Man Huang; Yao Wu; Ning Dong; Yong-Ming Yao
Journal:  J Cell Mol Med       Date:  2019-12-27       Impact factor: 5.310

Review 10.  Phagocytosis-Inflammation Crosstalk in Sepsis: New Avenues for Therapeutic Intervention.

Authors:  Marcela Hortová-Kohoutková; Federico Tidu; Marco De Zuani; Vladimír Šrámek; Martin Helán; Jan Frič
Journal:  Shock       Date:  2020-11       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.